@article{ref1,
title="Synthetic cannabinoids-further evidence supporting the relationship between cannabinoids and psychosis",
journal="Biological psychiatry",
year="2016",
author="Fattore, Liana",
volume="79",
number="7",
pages="539-548",
abstract="Consumption of synthetic mind-altering compounds, also known as &quot;new psychoactive substances,&quot; is increasing globally at an alarming rate. Synthetic cannabinoids (SCs) are among the most commonly used new psychoactive substances. They are usually purchased as marijuana-like drugs, marketed as herbal blends and perceived as risk-free by inexperienced users. Yet, contrary to Δ(9)-tetrahydrocannabinol, SCs may lead to severe health consequences, including anxiety, tachycardia, hallucinations, violent behavior, and psychosis. This review focuses on the latest (2010-2015) evidence of psychotic symptoms induced by ingestion of products containing SCs. Reports suggesting that SCs may either exacerbate previously stable psychotic symptoms (in vulnerable individuals) or trigger new-onset psychosis (in individuals with no previous history of psychosis) are reviewed. Pharmacology and toxicology of these compounds are discussed, with particular reference to their psychoactive effects.<br><br>Copyright © 2016 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.<p /> <p>Language: en</p>",
language="en",
issn="0006-3223",
doi="10.1016/j.biopsych.2016.02.001",
url="http://dx.doi.org/10.1016/j.biopsych.2016.02.001"
}